Your browser doesn't support javascript.
loading
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
Linder, Simon; Hoogstraat, Marlous; Stelloo, Suzan; Eickhoff, Nils; Schuurman, Karianne; de Barros, Hilda; Alkemade, Maartje; Bekers, Elise M; Severson, Tesa M; Sanders, Joyce; Huang, Chia-Chi Flora; Morova, Tunc; Altintas, Umut Berkay; Hoekman, Liesbeth; Kim, Yongsoo; Baca, Sylvan C; Sjöström, Martin; Zaalberg, Anniek; Hintzen, Dorine C; de Jong, Jeroen; Kluin, Roelof J C; de Rink, Iris; Giambartolomei, Claudia; Seo, Ji-Heui; Pasaniuc, Bogdan; Altelaar, Maarten; Medema, René H; Feng, Felix Y; Zoubeidi, Amina; Freedman, Matthew L; Wessels, Lodewyk F A; Butler, Lisa M; Lack, Nathan A; van der Poel, Henk; Bergman, Andries M; Zwart, Wilbert.
Afiliação
  • Linder S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hoogstraat M; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Stelloo S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Eickhoff N; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Schuurman K; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • de Barros H; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Alkemade M; Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Bekers EM; Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Severson TM; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Sanders J; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Huang CF; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Morova T; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Altintas UB; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
  • Hoekman L; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kim Y; School of Medicine, Koç University, Istanbul, Turkey.
  • Baca SC; Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey.
  • Sjöström M; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Zaalberg A; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Hintzen DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • de Jong J; The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts.
  • Kluin RJC; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
  • de Rink I; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Giambartolomei C; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Seo JH; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Pasaniuc B; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Altelaar M; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Medema RH; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Feng FY; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Zoubeidi A; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Wessels LFA; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Butler LM; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Lack NA; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van der Poel H; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, the Netherlands.
  • Bergman AM; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Zwart W; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Cancer Discov ; 12(9): 2074-2097, 2022 09 02.
Article em En | MEDLINE | ID: mdl-35754340
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Androgênios Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Androgênios Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article